Holen Sie sich die Stockscreener-App
1.29
0.38%
-0.01
Handel nachbörslich:
1.29
Schlusskurs vom Vortag:
$1.30
Offen:
$1.29
24-Stunden-Volumen:
2.11M
Relative Volume:
0.66
Marktkapitalisierung:
$319.35M
Einnahmen:
$95,000
Nettoeinkommen (Verlust:
$-327.27M
KGV:
-0.6085
EPS:
-2.12
Netto-Cashflow:
$-239.25M
1W Leistung:
-10.69%
1M Leistung:
+16.67%
6M Leistung:
-32.02%
1J Leistung:
-41.93%
1-Tages-Spanne:
$1.26
$1.36
1-Wochen-Bereich:
$1.26
$1.45
52-Wochen-Spanne:
$0.8621
$3.78
Allogene Therapeutics Inc Stock (ALLO) Company Profile
Firmenname
Allogene Therapeutics Inc
Sektor
Branche
Telefon
(650) 457-2700
Adresse
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Vergleichen Sie ALLO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
1.29 | 319.35M | 95,000 | -327.27M | -239.25M | -2.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.37 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
513.54 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.32 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
537.92 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
252.78 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-14 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | Hochstufung | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-08-08 | Fortgesetzt | Oppenheimer | Outperform |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-01-05 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-01-05 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-08 | Eingeleitet | Citigroup | Buy |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-01-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-01-06 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-12-12 | Herabstufung | BofA Securities | Buy → Underperform |
| 2022-08-10 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-07-15 | Hochstufung | Goldman | Neutral → Buy |
| 2022-06-03 | Eingeleitet | Robert W. Baird | Neutral |
| 2022-02-28 | Bestätigt | B. Riley Securities | Buy |
| 2021-10-20 | Eingeleitet | Cowen | Outperform |
| 2021-10-08 | Herabstufung | Goldman | Buy → Neutral |
| 2021-10-08 | Herabstufung | Stifel | Buy → Hold |
| 2021-09-23 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-06-21 | Fortgesetzt | Jefferies | Buy |
| 2021-05-20 | Hochstufung | Truist | Hold → Buy |
| 2021-05-14 | Eingeleitet | B. Riley Securities | Buy |
| 2021-01-26 | Hochstufung | Stifel | Hold → Buy |
| 2020-12-10 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-11-24 | Eingeleitet | BofA Securities | Buy |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-06-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-29 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-19 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2020-05-15 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-05-14 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-14 | Herabstufung | SunTrust | Buy → Hold |
| 2020-04-13 | Eingeleitet | SunTrust | Buy |
| 2020-03-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-05 | Eingeleitet | Stifel | Hold |
| 2020-02-24 | Eingeleitet | Berenberg | Hold |
| 2019-12-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2019-11-04 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-06-05 | Eingeleitet | ROTH Capital | Neutral |
| 2019-05-31 | Eingeleitet | Guggenheim | Neutral |
| 2019-05-23 | Eingeleitet | Stifel | Hold |
| 2019-03-29 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Allogene Therapeutics Inc Aktie (ALLO) Neueste Nachrichten
Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace
Allogene’s SWOT analysis: stock outlook amid clinical delays, promising data By Investing.com - Investing.com India
Allogene’s SWOT analysis: stock outlook amid clinical delays, promising data - Investing.com
Allogene's SWOT analysis: stock outlook amid clinical delays, promising data - Investing.com
Allogene Therapeutics falls after trial delay, rating downgrade post Q1 results - MSN
Insider Sell: Deborah Messemer Sells 36,885 Shares of Allogene T - GuruFocus
Why Is Allogene Therapeutics (ALLO) Up 52.2% Since Last Earnings Report? - Yahoo Finance
Shareholders May Find It Hard To Justify Increasing Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation For Now - simplywall.st
Allogene Therapeutics at Jefferies Conference: Delays and Optimism By Investing.com - Investing.com Canada
All You Need to Know About Allogene Therapeutics (ALLO) Rating Upgrade to Buy - Yahoo Finance
Allogene Therapeutic's ALLO-316 Shows Durable Responses in Advanced Renal Cell Carcinoma - CRISPR Medicine News
Allogene Therapeutics Presents Promising Phase 1 Data for ALLO-316 in Renal Cell Carcinoma - MSN
Citi maintains buy rating on Allogene stock following ASCO data - Investing.com Australia
Citi maintains buy rating on Allogene stock following ASCO data By Investing.com - Investing.com India
Allogene Therapeutics (ALLO) Showcases Promising Data from Phase 1 TRAVERSE Study | ALLO Stock News - GuruFocus
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting - GuruFocus
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO | ALLO Stock News - GuruFocus
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO - The Manila Times
Allogene Therapeutics Highlights Promising Phase 1 Results of ALLO-316 in Advanced Renal Cell Carcinoma at ASCO 2025 - Nasdaq
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses With Allo-316 In Heavily Pretreated Advanced Renal Cell Carcinoma At ASCO - marketscreener.com
Allogene Therapeutics: Buying Around A Potential ASCO Lazarus Moment - Seeking Alpha
Allogene Therapeutics: Still Looking Shaky, But Looking To Turn The Corner (Rating Upgrade) - Seeking Alpha
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Raises Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - Defense World
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Allogene at TD Cowen’s Summit: Strategic Insights on CAR T-Cell Therapy - Investing.com Canada
Allogene Therapeutics’s SWOT analysis: CAR-T pioneer’s stock faces pivotal year - Investing.com
Analysts Are Bullish on These Healthcare Stocks: Cidara Therapeutics (CDTX), Merus (MRUS) - The Globe and Mail
Allogene Therapeutics Announces Participation in Upcoming Invest - GuruFocus
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences - The Manila Times
Allogene Therapeutics Lines Up Strategic Presentations at Goldman Sachs, Jefferies Healthcare Events - Stock Titan
Allogene shares update on CAR T-cell therapies at ASCO meeting - Investing.com Australia
Allogene Therapeutics Announces ASCO 2025 Abstract Publication F - GuruFocus
Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel - The Manila Times
Allogene shares update on CAR T-cell therapies at ASCO meeting By Investing.com - Investing.com South Africa
Allogene Therapeutics Announces Upcoming Presentations at ASCO 2025 Featuring ALLO-316 and ALPHA3 Trial Data - Nasdaq
Undervalued Opportunities: 3 Penny Stocks With Market Caps Above $30M - simplywall.st
Allogene extends cash runway into 2027 while prioritizing ALPHA3 and clinical momentum - MSN
Finance Watch: Prime, Kyverna, Allogene And More Announce Job Cuts - insights.citeline.com
Citigroup Issues Pessimistic Forecast for Allogene Therapeutics (NASDAQ:ALLO) Stock Price - Defense World
Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff - BioPharma Dive
Allogene (ALLO) Sinks 16% on Downgrade, Trial Delays - GuruFocus
ALLO: Citigroup Lowers Price Target But Maintains Buy Rating | A - GuruFocus
Allogene Therapeutics (ALLO) Loses -31.94% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Finanzdaten der Allogene Therapeutics Inc-Aktie (ALLO)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.32%
0.98%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):